SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-016233
Filing Date
2022-11-03
Accepted
2022-11-03 16:05:55
Documents
69
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20220930x10q.htm   iXBRL 10-Q 1936617
2 EX-31.1 crvs-20220930xex31d1.htm EX-31.1 11898
3 EX-31.2 crvs-20220930xex31d2.htm EX-31.2 11836
4 EX-32.1 crvs-20220930xex32d1.htm EX-32.1 11817
  Complete submission text file 0001558370-22-016233.txt   6944021

Data Files

Seq Description Document Type Size
5 EX-101.SCH crvs-20220930.xsd EX-101.SCH 43637
6 EX-101.CAL crvs-20220930_cal.xml EX-101.CAL 49677
7 EX-101.DEF crvs-20220930_def.xml EX-101.DEF 147177
8 EX-101.LAB crvs-20220930_lab.xml EX-101.LAB 390547
9 EX-101.PRE crvs-20220930_pre.xml EX-101.PRE 286397
63 EXTRACTED XBRL INSTANCE DOCUMENT crvs-20220930x10q_htm.xml XML 1183280
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 221357918
SIC: 2834 Pharmaceutical Preparations